nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—Naftifine—Toremifene—breast cancer	0.207	0.614	CrCrCtD
Duloxetine—CYP2D6—breast cancer	0.139	1	CbGaD
Duloxetine—Naftifine—Tamoxifen—breast cancer	0.13	0.386	CrCrCtD
Duloxetine—HTR6—Raloxifene—breast cancer	0.0888	0.374	CbGbCtD
Duloxetine—CYP1A2—Anastrozole—breast cancer	0.0371	0.156	CbGbCtD
Duloxetine—CYP1A2—Toremifene—breast cancer	0.034	0.143	CbGbCtD
Duloxetine—CYP2D6—Idarubicin—breast cancer	0.0232	0.0977	CbGbCtD
Duloxetine—CYP1A2—Tamoxifen—breast cancer	0.0124	0.0523	CbGbCtD
Duloxetine—CYP2D6—Vinorelbine—breast cancer	0.0113	0.0477	CbGbCtD
Duloxetine—CYP2D6—Tamoxifen—breast cancer	0.0102	0.0431	CbGbCtD
Duloxetine—CYP1A2—Fluorouracil—breast cancer	0.00914	0.0385	CbGbCtD
Duloxetine—CYP2D6—Vinblastine—breast cancer	0.00698	0.0294	CbGbCtD
Duloxetine—CYP2D6—Doxorubicin—breast cancer	0.00429	0.0181	CbGbCtD
Duloxetine—NPY1R—nipple—breast cancer	0.000907	0.16	CbGeAlD
Duloxetine—NPY1R—pituitary gland—breast cancer	0.000496	0.0872	CbGeAlD
Duloxetine—NPY1R—adipose tissue—breast cancer	0.000494	0.0869	CbGeAlD
Duloxetine—NPY1R—female reproductive system—breast cancer	0.000454	0.0798	CbGeAlD
Duloxetine—NPY1R—adrenal gland—breast cancer	0.000443	0.0779	CbGeAlD
Duloxetine—NPY1R—endocrine gland—breast cancer	0.000384	0.0676	CbGeAlD
Duloxetine—NPY1R—lymph node—breast cancer	0.000265	0.0467	CbGeAlD
Duloxetine—CYP1A2—nipple—breast cancer	0.000237	0.0417	CbGeAlD
Duloxetine—Cinacalcet—CYP2D6—breast cancer	0.00023	0.127	CrCbGaD
Duloxetine—Protriptyline—CYP2D6—breast cancer	0.000215	0.119	CrCbGaD
Duloxetine—Cinacalcet—CYP3A4—breast cancer	0.000197	0.109	CrCbGaD
Duloxetine—HTR2C—female reproductive system—breast cancer	0.000184	0.0325	CbGeAlD
Duloxetine—SLC6A4—female reproductive system—breast cancer	0.000175	0.0308	CbGeAlD
Duloxetine—SLC6A2—female reproductive system—breast cancer	0.000154	0.0271	CbGeAlD
Duloxetine—Protriptyline—ABCB1—breast cancer	0.000154	0.0849	CrCbGaD
Duloxetine—HTR2A—embryo—breast cancer	0.000153	0.0269	CbGeAlD
Duloxetine—SLC6A2—adrenal gland—breast cancer	0.00015	0.0264	CbGeAlD
Duloxetine—SLC6A4—endocrine gland—breast cancer	0.000148	0.0261	CbGeAlD
Duloxetine—Fluoxetine—CYP2D6—breast cancer	0.000147	0.0811	CrCbGaD
Duloxetine—SLC6A2—endocrine gland—breast cancer	0.00013	0.0229	CbGeAlD
Duloxetine—Fluoxetine—CYP3A4—breast cancer	0.000126	0.0696	CrCbGaD
Duloxetine—HTR2A—epithelium—breast cancer	0.000125	0.0219	CbGeAlD
Duloxetine—Propranolol—CYP1A1—breast cancer	0.00012	0.0665	CrCbGaD
Duloxetine—Fluoxetine—ALB—breast cancer	0.00011	0.0607	CrCbGaD
Duloxetine—Fluoxetine—ABCB1—breast cancer	0.000105	0.0579	CrCbGaD
Duloxetine—HTR2A—pituitary gland—breast cancer	0.000101	0.0178	CbGeAlD
Duloxetine—CYP1A2—endocrine gland—breast cancer	0.0001	0.0176	CbGeAlD
Duloxetine—Atomoxetine—CYP2D6—breast cancer	9.44e-05	0.0521	CrCbGaD
Duloxetine—HTR2A—female reproductive system—breast cancer	9.25e-05	0.0163	CbGeAlD
Duloxetine—HTR2A—adrenal gland—breast cancer	9.03e-05	0.0159	CbGeAlD
Duloxetine—SLC6A2—lymph node—breast cancer	9.01e-05	0.0159	CbGeAlD
Duloxetine—Propranolol—CYP2D6—breast cancer	8.96e-05	0.0495	CrCbGaD
Duloxetine—CYP2D6—female reproductive system—breast cancer	8.43e-05	0.0148	CbGeAlD
Duloxetine—Atomoxetine—CYP3A4—breast cancer	8.09e-05	0.0447	CrCbGaD
Duloxetine—HTR2A—endocrine gland—breast cancer	7.83e-05	0.0138	CbGeAlD
Duloxetine—Propranolol—CYP3A4—breast cancer	7.69e-05	0.0425	CrCbGaD
Duloxetine—CYP2D6—female gonad—breast cancer	7.67e-05	0.0135	CbGeAlD
Duloxetine—CYP2D6—endocrine gland—breast cancer	7.13e-05	0.0126	CbGeAlD
Duloxetine—Propranolol—ABCB1—breast cancer	6.4e-05	0.0354	CrCbGaD
Duloxetine—Oedema peripheral—Doxorubicin—breast cancer	2.61e-05	0.000132	CcSEcCtD
Duloxetine—Dysgeusia—Methotrexate—breast cancer	2.61e-05	0.000132	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Docetaxel—breast cancer	2.6e-05	0.000132	CcSEcCtD
Duloxetine—Connective tissue disorder—Doxorubicin—breast cancer	2.6e-05	0.000132	CcSEcCtD
Duloxetine—Fatigue—Docetaxel—breast cancer	2.6e-05	0.000131	CcSEcCtD
Duloxetine—Angiopathy—Epirubicin—breast cancer	2.6e-05	0.000131	CcSEcCtD
Duloxetine—Urethral disorder—Doxorubicin—breast cancer	2.59e-05	0.000131	CcSEcCtD
Duloxetine—Nausea—Irinotecan—breast cancer	2.59e-05	0.000131	CcSEcCtD
Duloxetine—Nausea—Mitoxantrone—breast cancer	2.59e-05	0.000131	CcSEcCtD
Duloxetine—Immune system disorder—Epirubicin—breast cancer	2.58e-05	0.000131	CcSEcCtD
Duloxetine—Mediastinal disorder—Epirubicin—breast cancer	2.58e-05	0.00013	CcSEcCtD
Duloxetine—Pain—Docetaxel—breast cancer	2.58e-05	0.00013	CcSEcCtD
Duloxetine—Constipation—Docetaxel—breast cancer	2.58e-05	0.00013	CcSEcCtD
Duloxetine—Back pain—Methotrexate—breast cancer	2.57e-05	0.00013	CcSEcCtD
Duloxetine—Dyspepsia—Capecitabine—breast cancer	2.57e-05	0.00013	CcSEcCtD
Duloxetine—Chills—Epirubicin—breast cancer	2.57e-05	0.00013	CcSEcCtD
Duloxetine—Arrhythmia—Epirubicin—breast cancer	2.56e-05	0.000129	CcSEcCtD
Duloxetine—Visual impairment—Doxorubicin—breast cancer	2.55e-05	0.000129	CcSEcCtD
Duloxetine—Asthenia—Paclitaxel—breast cancer	2.55e-05	0.000129	CcSEcCtD
Duloxetine—Decreased appetite—Capecitabine—breast cancer	2.54e-05	0.000128	CcSEcCtD
Duloxetine—Alopecia—Epirubicin—breast cancer	2.53e-05	0.000128	CcSEcCtD
Duloxetine—Nausea—Gemcitabine—breast cancer	2.52e-05	0.000128	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Capecitabine—breast cancer	2.52e-05	0.000127	CcSEcCtD
Duloxetine—Fatigue—Capecitabine—breast cancer	2.52e-05	0.000127	CcSEcCtD
Duloxetine—Pruritus—Paclitaxel—breast cancer	2.52e-05	0.000127	CcSEcCtD
Duloxetine—Vision blurred—Methotrexate—breast cancer	2.51e-05	0.000127	CcSEcCtD
Duloxetine—Mental disorder—Epirubicin—breast cancer	2.51e-05	0.000127	CcSEcCtD
Duloxetine—Erythema multiforme—Doxorubicin—breast cancer	2.5e-05	0.000127	CcSEcCtD
Duloxetine—Pain—Capecitabine—breast cancer	2.49e-05	0.000126	CcSEcCtD
Duloxetine—Constipation—Capecitabine—breast cancer	2.49e-05	0.000126	CcSEcCtD
Duloxetine—Erythema—Epirubicin—breast cancer	2.49e-05	0.000126	CcSEcCtD
Duloxetine—Malnutrition—Epirubicin—breast cancer	2.49e-05	0.000126	CcSEcCtD
Duloxetine—Feeling abnormal—Docetaxel—breast cancer	2.48e-05	0.000126	CcSEcCtD
Duloxetine—Nausea—Fluorouracil—breast cancer	2.48e-05	0.000126	CcSEcCtD
Duloxetine—Eye disorder—Doxorubicin—breast cancer	2.47e-05	0.000125	CcSEcCtD
Duloxetine—Ill-defined disorder—Methotrexate—breast cancer	2.47e-05	0.000125	CcSEcCtD
Duloxetine—Tinnitus—Doxorubicin—breast cancer	2.47e-05	0.000125	CcSEcCtD
Duloxetine—Gastrointestinal pain—Docetaxel—breast cancer	2.46e-05	0.000125	CcSEcCtD
Duloxetine—Anaemia—Methotrexate—breast cancer	2.46e-05	0.000124	CcSEcCtD
Duloxetine—Flushing—Doxorubicin—breast cancer	2.46e-05	0.000124	CcSEcCtD
Duloxetine—Cardiac disorder—Doxorubicin—breast cancer	2.46e-05	0.000124	CcSEcCtD
Duloxetine—Flatulence—Epirubicin—breast cancer	2.45e-05	0.000124	CcSEcCtD
Duloxetine—Tension—Epirubicin—breast cancer	2.44e-05	0.000124	CcSEcCtD
Duloxetine—Dysgeusia—Epirubicin—breast cancer	2.44e-05	0.000123	CcSEcCtD
Duloxetine—Diarrhoea—Paclitaxel—breast cancer	2.43e-05	0.000123	CcSEcCtD
Duloxetine—Nervousness—Epirubicin—breast cancer	2.42e-05	0.000122	CcSEcCtD
Duloxetine—Back pain—Epirubicin—breast cancer	2.41e-05	0.000122	CcSEcCtD
Duloxetine—Feeling abnormal—Capecitabine—breast cancer	2.4e-05	0.000122	CcSEcCtD
Duloxetine—Angiopathy—Doxorubicin—breast cancer	2.4e-05	0.000122	CcSEcCtD
Duloxetine—Malaise—Methotrexate—breast cancer	2.4e-05	0.000121	CcSEcCtD
Duloxetine—Muscle spasms—Epirubicin—breast cancer	2.39e-05	0.000121	CcSEcCtD
Duloxetine—Immune system disorder—Doxorubicin—breast cancer	2.39e-05	0.000121	CcSEcCtD
Duloxetine—Vertigo—Methotrexate—breast cancer	2.39e-05	0.000121	CcSEcCtD
Duloxetine—Gastrointestinal pain—Capecitabine—breast cancer	2.39e-05	0.000121	CcSEcCtD
Duloxetine—Mediastinal disorder—Doxorubicin—breast cancer	2.39e-05	0.000121	CcSEcCtD
Duloxetine—Abdominal pain—Docetaxel—breast cancer	2.38e-05	0.000121	CcSEcCtD
Duloxetine—Body temperature increased—Docetaxel—breast cancer	2.38e-05	0.000121	CcSEcCtD
Duloxetine—Leukopenia—Methotrexate—breast cancer	2.38e-05	0.000121	CcSEcCtD
Duloxetine—Chills—Doxorubicin—breast cancer	2.37e-05	0.00012	CcSEcCtD
Duloxetine—Arrhythmia—Doxorubicin—breast cancer	2.36e-05	0.00012	CcSEcCtD
Duloxetine—Dizziness—Paclitaxel—breast cancer	2.35e-05	0.000119	CcSEcCtD
Duloxetine—Vision blurred—Epirubicin—breast cancer	2.35e-05	0.000119	CcSEcCtD
Duloxetine—Alopecia—Doxorubicin—breast cancer	2.34e-05	0.000118	CcSEcCtD
Duloxetine—Cough—Methotrexate—breast cancer	2.32e-05	0.000118	CcSEcCtD
Duloxetine—Mental disorder—Doxorubicin—breast cancer	2.32e-05	0.000117	CcSEcCtD
Duloxetine—Urticaria—Capecitabine—breast cancer	2.32e-05	0.000117	CcSEcCtD
Duloxetine—Ill-defined disorder—Epirubicin—breast cancer	2.31e-05	0.000117	CcSEcCtD
Duloxetine—Abdominal pain—Capecitabine—breast cancer	2.31e-05	0.000117	CcSEcCtD
Duloxetine—Body temperature increased—Capecitabine—breast cancer	2.31e-05	0.000117	CcSEcCtD
Duloxetine—Convulsion—Methotrexate—breast cancer	2.31e-05	0.000117	CcSEcCtD
Duloxetine—Erythema—Doxorubicin—breast cancer	2.3e-05	0.000117	CcSEcCtD
Duloxetine—Malnutrition—Doxorubicin—breast cancer	2.3e-05	0.000117	CcSEcCtD
Duloxetine—Anaemia—Epirubicin—breast cancer	2.3e-05	0.000116	CcSEcCtD
Duloxetine—Agitation—Epirubicin—breast cancer	2.29e-05	0.000116	CcSEcCtD
Duloxetine—Flatulence—Doxorubicin—breast cancer	2.27e-05	0.000115	CcSEcCtD
Duloxetine—Arthralgia—Methotrexate—breast cancer	2.27e-05	0.000115	CcSEcCtD
Duloxetine—Myalgia—Methotrexate—breast cancer	2.27e-05	0.000115	CcSEcCtD
Duloxetine—Chest pain—Methotrexate—breast cancer	2.27e-05	0.000115	CcSEcCtD
Duloxetine—Tension—Doxorubicin—breast cancer	2.26e-05	0.000114	CcSEcCtD
Duloxetine—Vomiting—Paclitaxel—breast cancer	2.26e-05	0.000114	CcSEcCtD
Duloxetine—Dysgeusia—Doxorubicin—breast cancer	2.26e-05	0.000114	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	2.25e-05	0.000114	CcSEcCtD
Duloxetine—Malaise—Epirubicin—breast cancer	2.25e-05	0.000114	CcSEcCtD
Duloxetine—Rash—Paclitaxel—breast cancer	2.24e-05	0.000113	CcSEcCtD
Duloxetine—Dermatitis—Paclitaxel—breast cancer	2.24e-05	0.000113	CcSEcCtD
Duloxetine—Discomfort—Methotrexate—breast cancer	2.24e-05	0.000113	CcSEcCtD
Duloxetine—Nervousness—Doxorubicin—breast cancer	2.24e-05	0.000113	CcSEcCtD
Duloxetine—Vertigo—Epirubicin—breast cancer	2.24e-05	0.000113	CcSEcCtD
Duloxetine—Syncope—Epirubicin—breast cancer	2.23e-05	0.000113	CcSEcCtD
Duloxetine—Leukopenia—Epirubicin—breast cancer	2.23e-05	0.000113	CcSEcCtD
Duloxetine—Back pain—Doxorubicin—breast cancer	2.23e-05	0.000113	CcSEcCtD
Duloxetine—Headache—Paclitaxel—breast cancer	2.23e-05	0.000113	CcSEcCtD
Duloxetine—Hypersensitivity—Docetaxel—breast cancer	2.22e-05	0.000112	CcSEcCtD
Duloxetine—Muscle spasms—Doxorubicin—breast cancer	2.22e-05	0.000112	CcSEcCtD
Duloxetine—Palpitations—Epirubicin—breast cancer	2.2e-05	0.000111	CcSEcCtD
Duloxetine—Confusional state—Methotrexate—breast cancer	2.19e-05	0.000111	CcSEcCtD
Duloxetine—Loss of consciousness—Epirubicin—breast cancer	2.19e-05	0.000111	CcSEcCtD
Duloxetine—Cough—Epirubicin—breast cancer	2.17e-05	0.00011	CcSEcCtD
Duloxetine—Anaphylactic shock—Methotrexate—breast cancer	2.17e-05	0.00011	CcSEcCtD
Duloxetine—Vision blurred—Doxorubicin—breast cancer	2.17e-05	0.00011	CcSEcCtD
Duloxetine—Asthenia—Docetaxel—breast cancer	2.16e-05	0.000109	CcSEcCtD
Duloxetine—Convulsion—Epirubicin—breast cancer	2.16e-05	0.000109	CcSEcCtD
Duloxetine—Infection—Methotrexate—breast cancer	2.16e-05	0.000109	CcSEcCtD
Duloxetine—Hypertension—Epirubicin—breast cancer	2.15e-05	0.000109	CcSEcCtD
Duloxetine—Hypersensitivity—Capecitabine—breast cancer	2.15e-05	0.000109	CcSEcCtD
Duloxetine—Ill-defined disorder—Doxorubicin—breast cancer	2.14e-05	0.000108	CcSEcCtD
Duloxetine—Pruritus—Docetaxel—breast cancer	2.13e-05	0.000108	CcSEcCtD
Duloxetine—Nervous system disorder—Methotrexate—breast cancer	2.13e-05	0.000108	CcSEcCtD
Duloxetine—Anaemia—Doxorubicin—breast cancer	2.13e-05	0.000108	CcSEcCtD
Duloxetine—Thrombocytopenia—Methotrexate—breast cancer	2.13e-05	0.000108	CcSEcCtD
Duloxetine—Arthralgia—Epirubicin—breast cancer	2.12e-05	0.000107	CcSEcCtD
Duloxetine—Chest pain—Epirubicin—breast cancer	2.12e-05	0.000107	CcSEcCtD
Duloxetine—Myalgia—Epirubicin—breast cancer	2.12e-05	0.000107	CcSEcCtD
Duloxetine—Agitation—Doxorubicin—breast cancer	2.12e-05	0.000107	CcSEcCtD
Duloxetine—Anxiety—Epirubicin—breast cancer	2.11e-05	0.000107	CcSEcCtD
Duloxetine—Nausea—Paclitaxel—breast cancer	2.11e-05	0.000107	CcSEcCtD
Duloxetine—Skin disorder—Methotrexate—breast cancer	2.11e-05	0.000107	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	2.11e-05	0.000107	CcSEcCtD
Duloxetine—Hyperhidrosis—Methotrexate—breast cancer	2.1e-05	0.000106	CcSEcCtD
Duloxetine—Discomfort—Epirubicin—breast cancer	2.09e-05	0.000106	CcSEcCtD
Duloxetine—Asthenia—Capecitabine—breast cancer	2.09e-05	0.000106	CcSEcCtD
Duloxetine—Malaise—Doxorubicin—breast cancer	2.08e-05	0.000105	CcSEcCtD
Duloxetine—Dry mouth—Epirubicin—breast cancer	2.07e-05	0.000105	CcSEcCtD
Duloxetine—Vertigo—Doxorubicin—breast cancer	2.07e-05	0.000105	CcSEcCtD
Duloxetine—Anorexia—Methotrexate—breast cancer	2.07e-05	0.000105	CcSEcCtD
Duloxetine—Syncope—Doxorubicin—breast cancer	2.07e-05	0.000105	CcSEcCtD
Duloxetine—Pruritus—Capecitabine—breast cancer	2.06e-05	0.000104	CcSEcCtD
Duloxetine—Leukopenia—Doxorubicin—breast cancer	2.06e-05	0.000104	CcSEcCtD
Duloxetine—Diarrhoea—Docetaxel—breast cancer	2.06e-05	0.000104	CcSEcCtD
Duloxetine—Confusional state—Epirubicin—breast cancer	2.05e-05	0.000104	CcSEcCtD
Duloxetine—Palpitations—Doxorubicin—breast cancer	2.04e-05	0.000103	CcSEcCtD
Duloxetine—Anaphylactic shock—Epirubicin—breast cancer	2.03e-05	0.000103	CcSEcCtD
Duloxetine—Oedema—Epirubicin—breast cancer	2.03e-05	0.000103	CcSEcCtD
Duloxetine—Loss of consciousness—Doxorubicin—breast cancer	2.03e-05	0.000102	CcSEcCtD
Duloxetine—Infection—Epirubicin—breast cancer	2.02e-05	0.000102	CcSEcCtD
Duloxetine—Cough—Doxorubicin—breast cancer	2.01e-05	0.000102	CcSEcCtD
Duloxetine—Shock—Epirubicin—breast cancer	2e-05	0.000101	CcSEcCtD
Duloxetine—Convulsion—Doxorubicin—breast cancer	2e-05	0.000101	CcSEcCtD
Duloxetine—Diarrhoea—Capecitabine—breast cancer	2e-05	0.000101	CcSEcCtD
Duloxetine—Nervous system disorder—Epirubicin—breast cancer	1.99e-05	0.000101	CcSEcCtD
Duloxetine—Dizziness—Docetaxel—breast cancer	1.99e-05	0.000101	CcSEcCtD
Duloxetine—Thrombocytopenia—Epirubicin—breast cancer	1.99e-05	0.000101	CcSEcCtD
Duloxetine—Hypertension—Doxorubicin—breast cancer	1.99e-05	0.000101	CcSEcCtD
Duloxetine—Tachycardia—Epirubicin—breast cancer	1.98e-05	0.0001	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Methotrexate—breast cancer	1.98e-05	0.0001	CcSEcCtD
Duloxetine—Skin disorder—Epirubicin—breast cancer	1.97e-05	9.99e-05	CcSEcCtD
Duloxetine—Hyperhidrosis—Epirubicin—breast cancer	1.96e-05	9.94e-05	CcSEcCtD
Duloxetine—Insomnia—Methotrexate—breast cancer	1.96e-05	9.94e-05	CcSEcCtD
Duloxetine—Myalgia—Doxorubicin—breast cancer	1.96e-05	9.93e-05	CcSEcCtD
Duloxetine—Arthralgia—Doxorubicin—breast cancer	1.96e-05	9.93e-05	CcSEcCtD
Duloxetine—Chest pain—Doxorubicin—breast cancer	1.96e-05	9.93e-05	CcSEcCtD
Duloxetine—Anxiety—Doxorubicin—breast cancer	1.95e-05	9.89e-05	CcSEcCtD
Duloxetine—Paraesthesia—Methotrexate—breast cancer	1.95e-05	9.87e-05	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.95e-05	9.86e-05	CcSEcCtD
Duloxetine—Discomfort—Doxorubicin—breast cancer	1.94e-05	9.81e-05	CcSEcCtD
Duloxetine—Anorexia—Epirubicin—breast cancer	1.94e-05	9.8e-05	CcSEcCtD
Duloxetine—Somnolence—Methotrexate—breast cancer	1.93e-05	9.77e-05	CcSEcCtD
Duloxetine—Dizziness—Capecitabine—breast cancer	1.93e-05	9.76e-05	CcSEcCtD
Duloxetine—Dry mouth—Doxorubicin—breast cancer	1.92e-05	9.71e-05	CcSEcCtD
Duloxetine—Vomiting—Docetaxel—breast cancer	1.92e-05	9.7e-05	CcSEcCtD
Duloxetine—Dyspepsia—Methotrexate—breast cancer	1.91e-05	9.68e-05	CcSEcCtD
Duloxetine—Rash—Docetaxel—breast cancer	1.9e-05	9.62e-05	CcSEcCtD
Duloxetine—Dermatitis—Docetaxel—breast cancer	1.9e-05	9.61e-05	CcSEcCtD
Duloxetine—Confusional state—Doxorubicin—breast cancer	1.9e-05	9.6e-05	CcSEcCtD
Duloxetine—Decreased appetite—Methotrexate—breast cancer	1.89e-05	9.55e-05	CcSEcCtD
Duloxetine—Headache—Docetaxel—breast cancer	1.89e-05	9.55e-05	CcSEcCtD
Duloxetine—Anaphylactic shock—Doxorubicin—breast cancer	1.88e-05	9.52e-05	CcSEcCtD
Duloxetine—Oedema—Doxorubicin—breast cancer	1.88e-05	9.52e-05	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Methotrexate—breast cancer	1.87e-05	9.49e-05	CcSEcCtD
Duloxetine—Fatigue—Methotrexate—breast cancer	1.87e-05	9.48e-05	CcSEcCtD
Duloxetine—Infection—Doxorubicin—breast cancer	1.87e-05	9.46e-05	CcSEcCtD
Duloxetine—Pain—Methotrexate—breast cancer	1.86e-05	9.4e-05	CcSEcCtD
Duloxetine—Vomiting—Capecitabine—breast cancer	1.85e-05	9.39e-05	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Epirubicin—breast cancer	1.85e-05	9.37e-05	CcSEcCtD
Duloxetine—Shock—Doxorubicin—breast cancer	1.85e-05	9.36e-05	CcSEcCtD
Duloxetine—Nervous system disorder—Doxorubicin—breast cancer	1.84e-05	9.33e-05	CcSEcCtD
Duloxetine—Thrombocytopenia—Doxorubicin—breast cancer	1.84e-05	9.32e-05	CcSEcCtD
Duloxetine—Rash—Capecitabine—breast cancer	1.84e-05	9.31e-05	CcSEcCtD
Duloxetine—Insomnia—Epirubicin—breast cancer	1.84e-05	9.3e-05	CcSEcCtD
Duloxetine—Dermatitis—Capecitabine—breast cancer	1.84e-05	9.3e-05	CcSEcCtD
Duloxetine—Tachycardia—Doxorubicin—breast cancer	1.84e-05	9.29e-05	CcSEcCtD
Duloxetine—Headache—Capecitabine—breast cancer	1.83e-05	9.25e-05	CcSEcCtD
Duloxetine—Skin disorder—Doxorubicin—breast cancer	1.83e-05	9.24e-05	CcSEcCtD
Duloxetine—Paraesthesia—Epirubicin—breast cancer	1.82e-05	9.24e-05	CcSEcCtD
Duloxetine—Hyperhidrosis—Doxorubicin—breast cancer	1.82e-05	9.2e-05	CcSEcCtD
Duloxetine—Somnolence—Epirubicin—breast cancer	1.81e-05	9.14e-05	CcSEcCtD
Duloxetine—Anorexia—Doxorubicin—breast cancer	1.79e-05	9.07e-05	CcSEcCtD
Duloxetine—Nausea—Docetaxel—breast cancer	1.79e-05	9.06e-05	CcSEcCtD
Duloxetine—Feeling abnormal—Methotrexate—breast cancer	1.79e-05	9.06e-05	CcSEcCtD
Duloxetine—Dyspepsia—Epirubicin—breast cancer	1.79e-05	9.05e-05	CcSEcCtD
Duloxetine—Gastrointestinal pain—Methotrexate—breast cancer	1.78e-05	8.99e-05	CcSEcCtD
Duloxetine—Decreased appetite—Epirubicin—breast cancer	1.77e-05	8.94e-05	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Epirubicin—breast cancer	1.75e-05	8.88e-05	CcSEcCtD
Duloxetine—Fatigue—Epirubicin—breast cancer	1.75e-05	8.87e-05	CcSEcCtD
Duloxetine—Constipation—Epirubicin—breast cancer	1.74e-05	8.8e-05	CcSEcCtD
Duloxetine—Pain—Epirubicin—breast cancer	1.74e-05	8.8e-05	CcSEcCtD
Duloxetine—Nausea—Capecitabine—breast cancer	1.73e-05	8.77e-05	CcSEcCtD
Duloxetine—Urticaria—Methotrexate—breast cancer	1.73e-05	8.73e-05	CcSEcCtD
Duloxetine—Abdominal pain—Methotrexate—breast cancer	1.72e-05	8.69e-05	CcSEcCtD
Duloxetine—Body temperature increased—Methotrexate—breast cancer	1.72e-05	8.69e-05	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.71e-05	8.67e-05	CcSEcCtD
Duloxetine—Insomnia—Doxorubicin—breast cancer	1.7e-05	8.61e-05	CcSEcCtD
Duloxetine—Paraesthesia—Doxorubicin—breast cancer	1.69e-05	8.55e-05	CcSEcCtD
Duloxetine—Feeling abnormal—Epirubicin—breast cancer	1.67e-05	8.48e-05	CcSEcCtD
Duloxetine—Somnolence—Doxorubicin—breast cancer	1.67e-05	8.46e-05	CcSEcCtD
Duloxetine—Gastrointestinal pain—Epirubicin—breast cancer	1.66e-05	8.41e-05	CcSEcCtD
Duloxetine—Dyspepsia—Doxorubicin—breast cancer	1.66e-05	8.38e-05	CcSEcCtD
Duloxetine—Decreased appetite—Doxorubicin—breast cancer	1.63e-05	8.27e-05	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Doxorubicin—breast cancer	1.62e-05	8.22e-05	CcSEcCtD
Duloxetine—Fatigue—Doxorubicin—breast cancer	1.62e-05	8.21e-05	CcSEcCtD
Duloxetine—Urticaria—Epirubicin—breast cancer	1.61e-05	8.17e-05	CcSEcCtD
Duloxetine—Pain—Doxorubicin—breast cancer	1.61e-05	8.14e-05	CcSEcCtD
Duloxetine—Constipation—Doxorubicin—breast cancer	1.61e-05	8.14e-05	CcSEcCtD
Duloxetine—Body temperature increased—Epirubicin—breast cancer	1.61e-05	8.13e-05	CcSEcCtD
Duloxetine—Abdominal pain—Epirubicin—breast cancer	1.61e-05	8.13e-05	CcSEcCtD
Duloxetine—Hypersensitivity—Methotrexate—breast cancer	1.6e-05	8.1e-05	CcSEcCtD
Duloxetine—Asthenia—Methotrexate—breast cancer	1.56e-05	7.89e-05	CcSEcCtD
Duloxetine—Feeling abnormal—Doxorubicin—breast cancer	1.55e-05	7.84e-05	CcSEcCtD
Duloxetine—Gastrointestinal pain—Doxorubicin—breast cancer	1.54e-05	7.78e-05	CcSEcCtD
Duloxetine—Pruritus—Methotrexate—breast cancer	1.54e-05	7.78e-05	CcSEcCtD
Duloxetine—Hypersensitivity—Epirubicin—breast cancer	1.5e-05	7.58e-05	CcSEcCtD
Duloxetine—Urticaria—Doxorubicin—breast cancer	1.49e-05	7.56e-05	CcSEcCtD
Duloxetine—Body temperature increased—Doxorubicin—breast cancer	1.49e-05	7.52e-05	CcSEcCtD
Duloxetine—Abdominal pain—Doxorubicin—breast cancer	1.49e-05	7.52e-05	CcSEcCtD
Duloxetine—Diarrhoea—Methotrexate—breast cancer	1.49e-05	7.52e-05	CcSEcCtD
Duloxetine—Asthenia—Epirubicin—breast cancer	1.46e-05	7.38e-05	CcSEcCtD
Duloxetine—Pruritus—Epirubicin—breast cancer	1.44e-05	7.28e-05	CcSEcCtD
Duloxetine—Dizziness—Methotrexate—breast cancer	1.44e-05	7.27e-05	CcSEcCtD
Duloxetine—Diarrhoea—Epirubicin—breast cancer	1.39e-05	7.04e-05	CcSEcCtD
Duloxetine—Hypersensitivity—Doxorubicin—breast cancer	1.39e-05	7.01e-05	CcSEcCtD
Duloxetine—Vomiting—Methotrexate—breast cancer	1.38e-05	6.99e-05	CcSEcCtD
Duloxetine—Rash—Methotrexate—breast cancer	1.37e-05	6.93e-05	CcSEcCtD
Duloxetine—Dermatitis—Methotrexate—breast cancer	1.37e-05	6.92e-05	CcSEcCtD
Duloxetine—Headache—Methotrexate—breast cancer	1.36e-05	6.89e-05	CcSEcCtD
Duloxetine—Asthenia—Doxorubicin—breast cancer	1.35e-05	6.83e-05	CcSEcCtD
Duloxetine—Dizziness—Epirubicin—breast cancer	1.34e-05	6.8e-05	CcSEcCtD
Duloxetine—Pruritus—Doxorubicin—breast cancer	1.33e-05	6.73e-05	CcSEcCtD
Duloxetine—Vomiting—Epirubicin—breast cancer	1.29e-05	6.54e-05	CcSEcCtD
Duloxetine—Nausea—Methotrexate—breast cancer	1.29e-05	6.53e-05	CcSEcCtD
Duloxetine—Diarrhoea—Doxorubicin—breast cancer	1.29e-05	6.51e-05	CcSEcCtD
Duloxetine—Rash—Epirubicin—breast cancer	1.28e-05	6.49e-05	CcSEcCtD
Duloxetine—Dermatitis—Epirubicin—breast cancer	1.28e-05	6.48e-05	CcSEcCtD
Duloxetine—Headache—Epirubicin—breast cancer	1.27e-05	6.44e-05	CcSEcCtD
Duloxetine—Dizziness—Doxorubicin—breast cancer	1.24e-05	6.29e-05	CcSEcCtD
Duloxetine—Nausea—Epirubicin—breast cancer	1.21e-05	6.11e-05	CcSEcCtD
Duloxetine—Vomiting—Doxorubicin—breast cancer	1.2e-05	6.05e-05	CcSEcCtD
Duloxetine—Rash—Doxorubicin—breast cancer	1.19e-05	6e-05	CcSEcCtD
Duloxetine—Dermatitis—Doxorubicin—breast cancer	1.18e-05	6e-05	CcSEcCtD
Duloxetine—Headache—Doxorubicin—breast cancer	1.18e-05	5.96e-05	CcSEcCtD
Duloxetine—Nausea—Doxorubicin—breast cancer	1.12e-05	5.65e-05	CcSEcCtD
Duloxetine—CYP1A2—Metabolism—ABCG2—breast cancer	4.23e-06	5.22e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGF1—breast cancer	4.22e-06	5.21e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CSF2—breast cancer	4.22e-06	5.21e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—RAF1—breast cancer	4.21e-06	5.2e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FGFR1—breast cancer	4.21e-06	5.19e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NRG1—breast cancer	4.19e-06	5.17e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—H2AFX—breast cancer	4.16e-06	5.13e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL2—breast cancer	4.16e-06	5.13e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—FASN—breast cancer	4.16e-06	5.13e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HPGDS—breast cancer	4.15e-06	5.12e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HIF1A—breast cancer	4.14e-06	5.11e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—BCHE—breast cancer	4.14e-06	5.11e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—E2F1—breast cancer	4.13e-06	5.1e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HBA1—breast cancer	4.12e-06	5.09e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOS3—breast cancer	4.11e-06	5.08e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CB—breast cancer	4.11e-06	5.07e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC5A5—breast cancer	4.09e-06	5.04e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LEP—breast cancer	4.04e-06	4.99e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ACHE—breast cancer	4.02e-06	4.97e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTT1—breast cancer	4.02e-06	4.97e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CAV1—breast cancer	4.01e-06	4.94e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SPP1—breast cancer	3.97e-06	4.9e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KDR—breast cancer	3.96e-06	4.89e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL8—breast cancer	3.95e-06	4.88e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NQO1—breast cancer	3.95e-06	4.87e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC2A1—breast cancer	3.95e-06	4.87e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ERBB3—breast cancer	3.92e-06	4.84e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CA—breast cancer	3.92e-06	4.84e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGFR2—breast cancer	3.92e-06	4.84e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MDM2—breast cancer	3.9e-06	4.82e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RAF1—breast cancer	3.89e-06	4.8e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RELA—breast cancer	3.87e-06	4.78e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ESR1—breast cancer	3.86e-06	4.76e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP3A4—breast cancer	3.85e-06	4.75e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ERBB2—breast cancer	3.85e-06	4.75e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FN1—breast cancer	3.81e-06	4.71e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP17A1—breast cancer	3.81e-06	4.7e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CB—breast cancer	3.8e-06	4.69e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MTOR—breast cancer	3.8e-06	4.69e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP1B1—breast cancer	3.78e-06	4.67e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL2—breast cancer	3.78e-06	4.66e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ENO1—breast cancer	3.77e-06	4.65e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS1—breast cancer	3.77e-06	4.65e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NFKBIA—breast cancer	3.77e-06	4.65e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TERT—breast cancer	3.76e-06	4.64e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	3.76e-06	4.64e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOTCH1—breast cancer	3.73e-06	4.61e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HSP90AA1—breast cancer	3.71e-06	4.58e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—breast cancer	3.71e-06	4.58e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2D6—breast cancer	3.7e-06	4.56e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGFR1—breast cancer	3.65e-06	4.51e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KIT—breast cancer	3.65e-06	4.5e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CG—breast cancer	3.65e-06	4.5e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APC—breast cancer	3.65e-06	4.5e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL8—breast cancer	3.65e-06	4.5e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NCOA2—breast cancer	3.63e-06	4.48e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HRAS—breast cancer	3.63e-06	4.47e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NCOA1—breast cancer	3.61e-06	4.46e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGF—breast cancer	3.61e-06	4.45e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HIF1A—breast cancer	3.6e-06	4.44e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1B—breast cancer	3.56e-06	4.4e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—STK11—breast cancer	3.56e-06	4.39e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP19A1—breast cancer	3.56e-06	4.39e-05	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—breast cancer	3.52e-06	4.35e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—FASN—breast cancer	3.52e-06	4.34e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LEP—breast cancer	3.51e-06	4.33e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—BCHE—breast cancer	3.51e-06	4.33e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—MAPK3—breast cancer	3.49e-06	4.31e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CASP3—breast cancer	3.49e-06	4.31e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL2—breast cancer	3.49e-06	4.3e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CAV1—breast cancer	3.48e-06	4.29e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—breast cancer	3.47e-06	4.28e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC5A5—breast cancer	3.46e-06	4.27e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KDR—breast cancer	3.44e-06	4.25e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BRAF—breast cancer	3.43e-06	4.23e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCND1—breast cancer	3.4e-06	4.2e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—JUN—breast cancer	3.39e-06	4.19e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CTNNB1—breast cancer	3.37e-06	4.15e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ESR1—breast cancer	3.35e-06	4.14e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NQO1—breast cancer	3.34e-06	4.13e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC2A1—breast cancer	3.34e-06	4.13e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF1—breast cancer	3.34e-06	4.12e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT2—breast cancer	3.34e-06	4.12e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EGFR—breast cancer	3.32e-06	4.1e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FN1—breast cancer	3.31e-06	4.09e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—COMT—breast cancer	3.31e-06	4.08e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—breast cancer	3.3e-06	4.07e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTP1—breast cancer	3.29e-06	4.06e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1A—breast cancer	3.29e-06	4.06e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTEN—breast cancer	3.28e-06	4.05e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	3.27e-06	4.04e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NFKBIA—breast cancer	3.27e-06	4.04e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP3A4—breast cancer	3.26e-06	4.03e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HMOX1—breast cancer	3.25e-06	4.01e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	3.24e-06	4e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOTCH1—breast cancer	3.24e-06	4e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ITPR1—breast cancer	3.24e-06	4e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK8—breast cancer	3.21e-06	3.96e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CD—breast cancer	3.21e-06	3.96e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP1B1—breast cancer	3.21e-06	3.96e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—breast cancer	3.2e-06	3.95e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CA—breast cancer	3.18e-06	3.92e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SERPINE1—breast cancer	3.17e-06	3.92e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KIT—breast cancer	3.17e-06	3.91e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APC—breast cancer	3.17e-06	3.91e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CG—breast cancer	3.17e-06	3.91e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HSP90AA1—breast cancer	3.14e-06	3.88e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—KRAS—breast cancer	3.14e-06	3.88e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGF—breast cancer	3.13e-06	3.87e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ABCB1—breast cancer	3.12e-06	3.85e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TYMS—breast cancer	3.06e-06	3.78e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NCOA1—breast cancer	3.06e-06	3.78e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SRC—breast cancer	3.04e-06	3.76e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAPK3—breast cancer	3.03e-06	3.75e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOS3—breast cancer	3.03e-06	3.74e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PLA2G4A—breast cancer	3.03e-06	3.73e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTM1—breast cancer	3.03e-06	3.73e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NCOR1—breast cancer	3.03e-06	3.73e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP19A1—breast cancer	3.01e-06	3.72e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—STK11—breast cancer	3.01e-06	3.72e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BRAF—breast cancer	2.98e-06	3.68e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—breast cancer	2.96e-06	3.66e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT3—breast cancer	2.93e-06	3.62e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1—breast cancer	2.9e-06	3.58e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT2—breast cancer	2.9e-06	3.58e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GPX1—breast cancer	2.9e-06	3.58e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EGFR—breast cancer	2.89e-06	3.56e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CA—breast cancer	2.89e-06	3.56e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MDM2—breast cancer	2.87e-06	3.55e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP1A1—breast cancer	2.87e-06	3.54e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RAF1—breast cancer	2.86e-06	3.53e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RELA—breast cancer	2.85e-06	3.52e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ERCC2—breast cancer	2.84e-06	3.51e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ERBB2—breast cancer	2.83e-06	3.5e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	2.83e-06	3.49e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK3—breast cancer	2.8e-06	3.46e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—COMT—breast cancer	2.8e-06	3.46e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CB—breast cancer	2.8e-06	3.45e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MTOR—breast cancer	2.8e-06	3.45e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTP1—breast cancer	2.79e-06	3.44e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CD—breast cancer	2.79e-06	3.44e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CA—breast cancer	2.76e-06	3.41e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SERPINE1—breast cancer	2.76e-06	3.4e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HMOX1—breast cancer	2.75e-06	3.4e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ITPR1—breast cancer	2.74e-06	3.39e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—KRAS—breast cancer	2.73e-06	3.37e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MYC—breast cancer	2.73e-06	3.37e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TGFB1—breast cancer	2.72e-06	3.36e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL8—breast cancer	2.69e-06	3.32e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MTHFR—breast cancer	2.67e-06	3.3e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HRAS—breast cancer	2.67e-06	3.29e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGFR—breast cancer	2.67e-06	3.29e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCB1—breast cancer	2.64e-06	3.26e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOS3—breast cancer	2.63e-06	3.25e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1B—breast cancer	2.62e-06	3.24e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—breast cancer	2.6e-06	3.2e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TYMS—breast cancer	2.59e-06	3.2e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CASP3—breast cancer	2.57e-06	3.17e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2—breast cancer	2.57e-06	3.17e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTM1—breast cancer	2.56e-06	3.16e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLA2G4A—breast cancer	2.56e-06	3.16e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NCOR1—breast cancer	2.56e-06	3.16e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—breast cancer	2.56e-06	3.15e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KRAS—breast cancer	2.52e-06	3.11e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CA—breast cancer	2.51e-06	3.09e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCND1—breast cancer	2.5e-06	3.09e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—JUN—breast cancer	2.5e-06	3.08e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MDM2—breast cancer	2.5e-06	3.08e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RAF1—breast cancer	2.49e-06	3.07e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CTNNB1—breast cancer	2.48e-06	3.06e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RELA—breast cancer	2.48e-06	3.06e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CAV1—breast cancer	2.47e-06	3.04e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ERBB2—breast cancer	2.46e-06	3.04e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GPX1—breast cancer	2.45e-06	3.03e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—breast cancer	2.43e-06	3e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP1A1—breast cancer	2.43e-06	3e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MTOR—breast cancer	2.43e-06	3e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CB—breast cancer	2.43e-06	3e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1A—breast cancer	2.42e-06	2.99e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTEN—breast cancer	2.42e-06	2.98e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ERCC2—breast cancer	2.41e-06	2.97e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK8—breast cancer	2.36e-06	2.92e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—breast cancer	2.36e-06	2.91e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL8—breast cancer	2.33e-06	2.88e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HRAS—breast cancer	2.32e-06	2.86e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CA—breast cancer	2.31e-06	2.86e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1B—breast cancer	2.28e-06	2.81e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MTHFR—breast cancer	2.27e-06	2.8e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—breast cancer	2.25e-06	2.78e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CG—breast cancer	2.25e-06	2.77e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SRC—breast cancer	2.24e-06	2.77e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—breast cancer	2.24e-06	2.76e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CASP3—breast cancer	2.23e-06	2.76e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2—breast cancer	2.23e-06	2.75e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—breast cancer	2.22e-06	2.74e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—breast cancer	2.18e-06	2.69e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCND1—breast cancer	2.17e-06	2.68e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JUN—breast cancer	2.17e-06	2.68e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT3—breast cancer	2.16e-06	2.67e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CTNNB1—breast cancer	2.15e-06	2.66e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HRAS—breast cancer	2.14e-06	2.64e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—breast cancer	2.11e-06	2.6e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1A—breast cancer	2.1e-06	2.6e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTEN—breast cancer	2.1e-06	2.59e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CAV1—breast cancer	2.09e-06	2.58e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK3—breast cancer	2.06e-06	2.55e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK8—breast cancer	2.05e-06	2.53e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—breast cancer	2.05e-06	2.53e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—breast cancer	2.05e-06	2.53e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MYC—breast cancer	2.01e-06	2.48e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TGFB1—breast cancer	2e-06	2.47e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2e-06	2.46e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CD—breast cancer	1.98e-06	2.44e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGFR—breast cancer	1.96e-06	2.42e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALB—breast cancer	1.95e-06	2.41e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SRC—breast cancer	1.95e-06	2.4e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CG—breast cancer	1.9e-06	2.35e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—breast cancer	1.9e-06	2.34e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—breast cancer	1.89e-06	2.33e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT3—breast cancer	1.88e-06	2.32e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NOS3—breast cancer	1.87e-06	2.3e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KRAS—breast cancer	1.86e-06	2.29e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK3—breast cancer	1.79e-06	2.21e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MYC—breast cancer	1.74e-06	2.15e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFB1—breast cancer	1.74e-06	2.15e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CB—breast cancer	1.72e-06	2.12e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—breast cancer	1.71e-06	2.11e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGFR—breast cancer	1.71e-06	2.1e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CA—breast cancer	1.7e-06	2.1e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CD—breast cancer	1.67e-06	2.07e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALB—breast cancer	1.65e-06	2.04e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—breast cancer	1.65e-06	2.04e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KRAS—breast cancer	1.61e-06	1.99e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NOS3—breast cancer	1.58e-06	1.95e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HRAS—breast cancer	1.58e-06	1.95e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—breast cancer	1.51e-06	1.86e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTEN—breast cancer	1.49e-06	1.84e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CA—breast cancer	1.48e-06	1.83e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CB—breast cancer	1.46e-06	1.8e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—breast cancer	1.45e-06	1.78e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—breast cancer	1.43e-06	1.77e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—breast cancer	1.39e-06	1.72e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HRAS—breast cancer	1.37e-06	1.69e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—breast cancer	1.31e-06	1.62e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTEN—breast cancer	1.26e-06	1.56e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—breast cancer	1.21e-06	1.49e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CA—breast cancer	1.05e-06	1.3e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CA—breast cancer	8.89e-07	1.1e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—breast cancer	8.57e-07	1.06e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—breast cancer	7.26e-07	8.96e-06	CbGpPWpGaD
